Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Taysha Gene Therapies, Inc. (TSHA) had Income from Continuous Operations of $-32.73M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-32.73M |
|
-- |
|
-- |
|
$34.02M |
|
$-34.02M |
|
$1.29M |
|
$-32.73M |
|
$-32.73M |
|
$-32.73M |
|
|
Income from Continuous Operations |
$-32.73M |
$-32.73M |
|
$-32.73M |
|
$-34.02M |
|
$-33.74M |
|
353.31M |
|
353.31M |
|
$-0.09 |
|
$-0.09 |
|
| Balance Sheet Financials | |
$299.95M |
|
$6.80M |
|
$16.60M |
|
$316.55M |
|
$28.63M |
|
$50.85M |
|
$68.93M |
|
$97.56M |
|
$218.99M |
|
$218.99M |
|
$218.99M |
|
273.92M |
|
| Cash Flow Statement Financials | |
$-66.37M |
|
$-0.36M |
|
$225.03M |
|
$141.64M |
|
$299.94M |
|
$158.31M |
|
$9.77M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.48 |
|
-- |
|
-- |
|
0.19 |
|
0.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-66.86M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.95% |
|
-14.95% |
|
-10.34% |
|
-12.13% |
|
$0.80 |
|
$-0.19 |
|
$-0.19 |
|